Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Towards a Cancer Mission in Horizon Europe.

Berns A, Ringborg U, Eggermont A, Baumann M, Calvo F, Eggert A, Espina C, Hanahan D, Lacombe D, de Lorenzo F, Oberst S, Philip T, Schüz J, Tabernero J, Celis JE.

Mol Oncol. 2019 Nov;13(11):2301-2304. doi: 10.1002/1878-0261.12585. No abstract available.

2.

Boosting the social impact of innovative cancer research - towards a mission-oriented approach to cancer.

Ringborg U, Celis JE, Baumann M, Eggermont A, Wild CP, Berns A.

Mol Oncol. 2019 Mar;13(3):497-501. doi: 10.1002/1878-0261.12464. Epub 2019 Feb 27. No abstract available.

3.

Cancer Core Europe: A translational research infrastructure for a European mission on cancer.

Eggermont AMM, Apolone G, Baumann M, Caldas C, Celis JE, de Lorenzo F, Ernberg I, Ringborg U, Rowell J, Tabernero J, Voest E, Calvo F.

Mol Oncol. 2019 Mar;13(3):521-527. doi: 10.1002/1878-0261.12447. Epub 2019 Feb 2. Review.

4.

Translational cancer research - a coherent cancer research continuum.

Ringborg U.

Mol Oncol. 2019 Mar;13(3):517-520. doi: 10.1002/1878-0261.12450. Epub 2019 Feb 1. Review.

5.

European Academy of Cancer Sciences - position paper.

Adami HO, Berns A, Celis JE, de Vries E, Eggermont A, Harris A, Zur Hausen H, Pelicci PG, Ringborg U.

Mol Oncol. 2018 Nov;12(11):1829-1837. doi: 10.1002/1878-0261.12379. Epub 2018 Sep 21.

6.

Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century.

Calvo F, Apolone G, Baumann M, Caldas C, Celis JE, de Lorenzo F, Ernberg I, Ringborg U, Rowell J, Tabernero J, Voest E, Eggermont A.

Eur J Cancer. 2018 Nov;103:155-159. doi: 10.1016/j.ejca.2018.08.023. Epub 2018 Sep 18.

PMID:
30241002
7.

Thomas Tursz (1946-2018).

Ringborg U, Celis JE.

Mol Oncol. 2018 Sep;12(9):1413-1414. doi: 10.1002/1878-0261.12361. Epub 2018 Aug 2. No abstract available.

8.

Quality control and improvement of cancer care: what is needed? 4th European Roundtable Meeting (ERTM) May 5th, 2017, Berlin, Germany.

Ortmann O, Helbig U, Torode J, Schreck S, Karjalainen S, Bettio M, Ringborg U, Klinkhammer-Schalke M, Bray F; participants of the ERTM.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1097-1102. doi: 10.1007/s00432-018-2638-0. Epub 2018 Apr 9. Review.

PMID:
29633019
9.

European Academy of Cancer Sciences-Designation of Comprehensive Cancer Centres of Excellence.

Ringborg U, Celis J, Eggermont A, Berns A.

Eur J Cancer. 2018 Apr;93:138-139. doi: 10.1016/j.ejca.2018.01.003. Epub 2018 Feb 14. No abstract available.

PMID:
29454744
10.

Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

Rajan A, Berns A, Ringborg U, Celis J, Ponder B, Caldas C, Livingston D, Bristow RG, Hecht TT, Tursz T, van Luenen H, Bono P, Helander T, Seamon K, Smyth JF, Louvard D, Eggermont A, van Harten WH.

Mol Oncol. 2016 May;10(5):645-51. doi: 10.1016/j.molonc.2015.12.007. Epub 2015 Dec 23. Review.

11.

Optimizing sharing of hospital biobank samples.

Riegman PH, de Jong B, Daidone MG, Söderström T, Thompson J, Hall JA, Mendy M, Ten Hoeve J, Broeks A, Reed W, Morente MM, López-Guerrero JA, Collins VP, Rogan J, Ringborg U.

Sci Transl Med. 2015 Jul 22;7(297):297fs31. doi: 10.1126/scitranslmed.3009279.

PMID:
26203078
12.

Innovative clinical trials for development of personalized cancer medicine.

Mendelsohn J, Ringborg U, Schilsky R.

Mol Oncol. 2015 May;9(5):933-4. doi: 10.1016/j.molonc.2015.02.013. Epub 2015 Mar 5. No abstract available.

13.

Translational cancer research: balancing prevention and treatment to combat cancer globally.

Wild CP, Bucher JR, de Jong BW, Dillner J, von Gertten C, Groopman JD, Herceg Z, Holmes E, Holmila R, Olsen JH, Ringborg U, Scalbert A, Shibata T, Smith MT, Ulrich C, Vineis P, McLaughlin J.

J Natl Cancer Inst. 2014 Dec 16;107(1):353. doi: 10.1093/jnci/dju353. Print 2015 Jan.

14.

Cancer Core Europe: a first step towards a virtual cancer institute in Europe?

Celis JE, Ringborg U.

Mol Oncol. 2014 Oct;8(7):1161-2. doi: 10.1016/j.molonc.2014.09.004. Epub 2014 Sep 18. No abstract available.

15.

Cancer Core Europe: a consortium to address the cancer care-cancer research continuum challenge.

Eggermont AM, Caldas C, Ringborg U, Medema R, Tabernero J, Wiestler O.

Eur J Cancer. 2014 Nov;50(16):2745-6. doi: 10.1016/j.ejca.2014.07.025. Epub 2014 Sep 25.

PMID:
25263570
16.

Pioneering quality assessment in European cancer centers: a data analysis of the organization for European cancer institutes accreditation and designation program.

Saghatchian M, Thonon F, Boomsma F, Hummel H, Koot B, Harrison C, Rajan A, de Valeriola D, Otter R, Laranja Pontes J, Lombardo C, McGrath E, Ringborg U, Tursz T, van Harten W.

J Oncol Pract. 2014 Sep;10(5):e342-9. doi: 10.1200/JOP.2013.001331. Epub 2014 Aug 12.

PMID:
25118210
17.

Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.

Tsimberidou AM, Ringborg U, Schilsky RL.

Am Soc Clin Oncol Educ Book. 2013:118-25. doi: 10.1200/EdBook_AM.2013.33.118. Review.

18.

[The ethical review committees should become a single authority].

Munck J, Dahlquist G, Johansson G, Petersson B, Ringborg U.

Lakartidningen. 2013 Apr 10-16;110(15):773-4. Swedish. No abstract available.

PMID:
23662543
19.

Personalized cancer medicine - a strategy to counteract an increasing cancer challenge.

Mendelsohn J, Ringborg U, Schilsky RL.

Mol Oncol. 2012 Apr;6(2):109-10. doi: 10.1016/j.molonc.2012.03.002. Epub 2012 Mar 13. No abstract available.

20.

EurocanPlatform, an FP7 project of the European Commission-first year commentary.

McVie G, Ringborg U.

Ecancermedicalscience. 2012 Mar 13;6:ed13. doi: 10.3332/ecancer.2012.ed13. eCollection 2012. No abstract available.

21.

2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial.

Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, Månsson-Brahme E, Ingvar C, Ringborg U.

Lancet. 2011 Nov 5;378(9803):1635-42. doi: 10.1016/S0140-6736(11)61546-8. Epub 2011 Oct 23. Erratum in: Lancet. 2011 Nov 5;378(9803):1626.

PMID:
22027547
22.

[Correct about skin cancer costs].

Lindelöf B, Hedblad MA, Ringborg U.

Lakartidningen. 2009 Apr 7-21;106(15-16):1112. Swedish. No abstract available.

PMID:
19492681
23.

Species-specific in vivo engraftment of the human BL melanoma cell line results in an invasive dedifferentiated phenotype not present in xenografts.

Cedervall J, Jamil S, Prasmickaite L, Cheng Y, Eskandarpour M, Hansson J, Maelandsmo GM, Ringborg U, Gulyas M, Zhen HS, Kanter L, Ahrlund-Richter L.

Cancer Res. 2009 May 1;69(9):3746-54. doi: 10.1158/0008-5472.CAN-08-3746. Epub 2009 Apr 21.

24.

The Stockholm declaration.

Ringborg U.

Mol Oncol. 2008 Jun;2(1):10-1. doi: 10.1016/j.molonc.2008.03.004. Epub 2008 Mar 21. No abstract available.

25.

The Stockholm declaration signals a cultural change in Europe's approach to cancer research. An interview with Ulrik Ringborg.

Ringborg U.

Mol Oncol. 2008 Jun;2(1):8-9. doi: 10.1016/j.molonc.2008.03.008. Epub 2008 Apr 3. No abstract available.

26.

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Platz A, Egyhazi S, Ringborg U, Hansson J.

Mol Oncol. 2008 Apr;1(4):395-405. doi: 10.1016/j.molonc.2007.12.003. Epub 2007 Dec 28.

27.

[Nevus or malignant melanoma? Correct diagnostic competence results in lower costs].

Lindelöf B, Hedblad MA, Ringborg U.

Lakartidningen. 2008 Sep 24-30;105(39):2666-9. Swedish. No abstract available.

PMID:
18846872
28.

Need for global action for cancer control.

Boyle P, Anderson BO, Andersson LC, Ariyaratne Y, Auleley GR, Barbacid M, Bartelink H, Baselga J, Behbehani K, Belardelli F, Berns A, Bishop J, Brawley O, Burns H, Clanton M, Cox B, Currow D, Dangou JM, de Valeriola D, Dinshaw K, Eggermont A, Fitzpatrick J, Forstmane M, Garaci E, Gavin AT, Kakizoe T, Kasler M, Keita N, Kerr D, Khayat D, Khleif S, Khuhaprema T, Knezevic T, Kubinova R, Mallath M, Martin-Moreno J, McCance D, McVie JG, Merriman A, Ngoma T, Nowacki M, Orgelbrand J, Park JG, Pierotti M, Ashton LP, Puska P, Escobar CV, Rajan B, Rajkumar T, Ringborg U, Robertson C, Rodger A, Roovali L, Santini LA, Sarhan M, Seffrin J, Semiglazov V, Shrestha BM, Soo KC, Stamenic V, Tamblyn C, Thomas R, Tuncer M, Tursz T, Vaitkiene R, Vallejos C, Veronesi U, Wojtyla A, Yach D, Yoo KY, Zatonski W, Zaridze D, Zeng YX, Zhao P, Zheng T.

Ann Oncol. 2008 Sep;19(9):1519-21. doi: 10.1093/annonc/mdn426. No abstract available.

PMID:
18723552
29.

Towards quality, comprehensiveness and excellence. The accreditation project of the Organisation of European Cancer Institutes (OECI).

Saghatchian M, Hummel H, Otter R, de Valeriola D, Van Harten W, Paradiso A, Koot B, Ringborg U, Tursz T; Organisation of European Cancer Institutes.

Tumori. 2008 Mar-Apr;94(2):164-71.

PMID:
18564602
30.

Improvement of European translational cancer research. Collaboration between comprehensive cancer centers.

Ringborg U, de Valeriola D, van Harten W, Bosch AL, Lombardo C, Nilsson K, Philip T, Pierotti MA, Riegman P, Saghatchian M, Storme G, Tursz T, Verellen D.

Tumori. 2008 Mar-Apr;94(2):143-6.

PMID:
18564598
31.

Managing cancer in the EU: the Organisation of European Cancer Institutes (OECI).

Ringborg U, Pierotti M, Storme G, Tursz T; European Economic Interest Grouping.

Eur J Cancer. 2008 Apr;44(6):772-3. doi: 10.1016/j.ejca.2008.01.012. Epub 2008 Mar 11.

PMID:
18337086
32.

Swedish oncology. Past--present--future.

Ringborg U.

Acta Oncol. 2008;47(2):171-5. doi: 10.1080/02841860701760098. No abstract available.

PMID:
18210294
33.

Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program.

Hansson J, Bergenmar M, Hofer PA, Lundell G, Månsson-Brahme E, Ringborg U, Synnerstad I, Bratel AT, Wennberg AM, Rosdahl I.

J Clin Oncol. 2007 Jul 1;25(19):2819-24.

PMID:
17602087
34.
35.

Harmonizing cancer control in Europe.

Ringborg U.

Adv Exp Med Biol. 2006;587:87-93. Review.

PMID:
17163158
36.

Tobacco: deadly in any form or disguise.

Boyle P, Ariyaratne MA, Barrington R, Bartelink H, Bartsch G, Berns A, de Valeriola D, Dinshaw KA, Eggermont AM, Gray N, Kakizoe T, Karki BS, Kaslar M, Kerr DJ, Khayat D, Khuhaprema T, Kim IH, Martin-Moreno J, McVie G, Park JG, Philip T, Ringborg U, Rodger A, Seffrin JR, Semiglazov V, Soo KC, Sun YT, Thomas R, Tursz T, Veronesi U, Wiestler O, Yoo KY, Zatonski W, Zhao P.

Lancet. 2006 May 27;367(9524):1710-2. No abstract available.

PMID:
16731252
37.

Mutations of PIK3CA are rare in cutaneous melanoma.

Omholt K, Kröckel D, Ringborg U, Hansson J.

Melanoma Res. 2006 Apr;16(2):197-200.

PMID:
16567976
38.

A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe.

Bataille V, Boniol M, De Vries E, Severi G, Brandberg Y, Sasieni P, Cuzick J, Eggermont A, Ringborg U, Grivegnée AR, Coebergh JW, Chignol MC, Doré JF, Autier P.

Eur J Cancer. 2005 Sep;41(14):2141-9.

PMID:
16125927
39.

Development of light ion therapy at the Karolinska Hospital and Institute.

Svensson H, Ringborg U, Näslund I, Brahme A.

Radiother Oncol. 2004 Dec;73 Suppl 2:S206-10.

PMID:
15971343
40.

Hadrontherapy with carbon12: radiotherapy of the near future.

Auberger T, Debus J, Gérard JP, Orecchia R, Pötter R, Remillieux J, Ringborg U, Wambersie A.

Radiother Oncol. 2004 Dec;73 Suppl 2:i-ii. No abstract available.

PMID:
15971300
41.

Curbing tobacco's toll starts with the professionals: World No Tobacco Day.

Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kásler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Pötschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W, Zeng YX.

Lancet. 2005 Jun 11-17;365(9476):1990-2. No abstract available.

PMID:
15950704
42.

Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations.

Gillgren P, Brattström G, Frisell J, Persson JO, Ringborg U, Hansson J.

Melanoma Res. 2005 Apr;15(2):125-32.

PMID:
15846146
43.

Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.

Grafström E, Egyházi S, Ringborg U, Hansson J, Platz A.

Clin Cancer Res. 2005 Apr 15;11(8):2991-7.

44.

p53 protein expression and TP53 mutations in malignant melanomas of sun-sheltered mucosal membranes versus chronically sun-exposed skin.

Ragnarsson-Olding B, Platz A, Olding L, Ringborg U.

Melanoma Res. 2004 Oct;14(5):395-401.

PMID:
15457096
45.

Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies.

Egyházi S, Bjöhle J, Skoog L, Huang F, Borg AL, Frostvik Stolt M, Hägerström T, Ringborg U, Bergh J.

Clin Chem. 2004 May;50(5):975-6. No abstract available.

46.

NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Omholt K, Platz A, Kanter L, Ringborg U, Hansson J.

Clin Cancer Res. 2003 Dec 15;9(17):6483-8.

47.

Cancer of the skin: a forgotten problem in Europe.

Boyle P, Doré JF, Autier P, Ringborg U.

Ann Oncol. 2004 Jan;15(1):5-6. No abstract available.

PMID:
14679111
48.

Radiotherapy and cancer care in Sweden.

Möller TR, Einhorn N, Lindholm C, Ringborg U, Svensson H; SBU Survey Group.

Acta Oncol. 2003;42(5-6):366-75.

PMID:
14596500
49.

The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001--summary and conclusions.

Ringborg U, Bergqvist D, Brorsson B, Cavallin-Ståhl E, Ceberg J, Einhorn N, Frödin JE, Järhult J, Lamnevik G, Lindholm C, Littbrand B, Norlund A, Nylén U, Rosén M, Svensson H, Möller TR.

Acta Oncol. 2003;42(5-6):357-65. Review.

PMID:
14596499
50.

O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.

Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J.

Br J Cancer. 2003 Oct 20;89(8):1517-23.

Supplemental Content

Loading ...
Support Center